Navigation Links
Jazz Pharmaceuticals Announces Third Quarter 2012 Results
Date:11/8/2012

ny believes that, similar to the presentation of adjusted net income and adjusted net income per diluted share, these non-GAAP financial measures are also helpful in understanding the company's 2012 financial guidance, particularly in light of the effect of various acquisition and divestiture transactions effected by the company during 2012. They are not meant to be considered in isolation or as a substitute for comparable GAAP measures, and should be read in conjunction with the consolidated financial statements prepared in accordance with GAAP. 

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995This press release contains forward-looking statements, including, but not limited to, statements related to Jazz Pharmaceuticals' future financial results and growth potential, including 2012 financial guidance, future product development and other statements that are not historical facts.  These forward-looking statements are based on Jazz Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with maintaining and increasing sales of and revenue from Xyrem, such as the potential introduction of generic competition and changed or increased regulatory restrictions on Xyrem, as well as similar risks related to effectively commercializing the company's other marketed products, including Erwinaze and Prialt; successfully integrating and growing Jazz Pharmaceuticals' combined business operations after the Azur Pharma merger and EUSA Pharma acquisition, which may be more difficult, time-consuming or costly than expected, particularly in light of the company's expanded international footprint; obtaining appropriate pricing and reimbursement for the compan
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Harwood Feffer LLP Announces Investigation of DUSA Pharmaceuticals, Inc.
2. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
3. Isis Pharmaceuticals To Present At The 2012 Credit Suisse Healthcare Conference
4. Savient Pharmaceuticals Reports Third Quarter 2012 Financial Results
5. Genoa Pharmaceuticals announces $1.2M Financing
6. Inovio Pharmaceuticals Reports 2012 Third Quarter Financial Results
7. Arisaph Pharmaceuticals Reports Positive Results From Two Safety Clinical Trials For Its Niacin Analog (ARI-3037MO)
8. Oramed Pharmaceuticals to Present at the 12th Annual Diabetes Technology Society Meeting in Bethesda, MD, Nov 8-10, 2012
9. Optimer Pharmaceuticals to Present at November 2012 Investor Conferences
10. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
11. Isis Pharmaceuticals To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 2015 Celtaxsys, Inc., a clinical stage pharmaceutical ... rare and orphan inflammatory disease indications, announced today that ... Drug Administration (FDA) to begin a Phase 2 clinical ... adult CF patients in the US. The regulatory submissions ... will be filed soon after. This groundbreaking clinical ...
(Date:7/6/2015)... SOUTH SAN FRANCISCO, Calif. , July 6, 2015 ... leading global pharmaceutical company, and Oculeve, a development-stage medical ... eye disease, today announced that they have entered into ... an all-cash transaction.  Under the terms of the agreement, ... payment and commercialization milestone payments related to Oculeve,s lead ...
(Date:7/6/2015)... SHENZHEN, China , July 6, 2015 China ... CNIT), a leading provider of integrated cloud-based platform, exchange, ... , today announced that the Company launched its mobile ... age of accessible healthcare services on mobile devices. The ... District Health and Family Planning Bureau and Shenzhen News ...
Breaking Medicine Technology:Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 2Allergan to Acquire Oculeve Dry Eye Disease Development Programs 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 4CNIT Launches the Mobile App for Healthcare One Pass 2CNIT Launches the Mobile App for Healthcare One Pass 3CNIT Launches the Mobile App for Healthcare One Pass 4
... 8 Cell Therapeutics, Inc. (CTI),(Nasdaq and ... data for the,Zevalin(R) ([90Y]-ibritumomab tiuxetan) First-line Indolent ... Hematology (ASH) 50th Annual Meeting by,Morschhauser, et ... (PFS) following Zevalin consolidation therapy for patients ...
... Patients with non-valvular,atrial fibrillation receiving either 30 mg ... oral Factor Xa inhibitor, experienced comparable,safety and tolerability ... II data presented today at the 50th Annual ... Francisco. These findings are the first results,from ...
Cached Medicine Technology:Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 2Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 3Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 4Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 5New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation 2New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation 3New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation 4New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation 5
(Date:7/7/2015)... ... 07, 2015 , ... Nationally-renowned attorneys in the realm of ... Invokana Ketoacidosis Lawsuit Center . The website provides information on Invokana side ... wishing to learn more about Invokana lawsuits for kidney problems, ketoacidosis, heart attack, ...
(Date:7/7/2015)... ... July 07, 2015 , ... Clarion ... labels, has been featured in the latest issue of In Compliance Magazine, a ... In Compliance delivers the latest news, standards updates, technical explanations and guidance, ...
(Date:7/7/2015)... ... 2015 , ... CareSync proudly announces today that Amy Gleason, ... House as a “Champion of Change” for Precision Medicine on Wednesday, July 8th. ... Change program recognizes Gleason and eight other extraordinary individuals who are making great ...
(Date:7/7/2015)... ... 2015 , ... Each year the Holiday Inn Westbury donates many ... and international level; however, the Holiday Inn now hosts one large event at the ... the beneficiaries. In September of 2014 they hosted an event with all proceeds going ...
(Date:7/6/2015)... ... July 07, 2015 , ... Currently, mobile testing is ... AIDS, advances in the molecular diagnostic technologies, wide availability of immunosuppressive drugs and ... technologies and genetic engineering also open lucrative opportunities for the market players. , ...
Breaking Medicine News(10 mins):Health News:National Attorneys Launch Invokana Ketoacidosis Lawsuit Center 2Health News:National Attorneys Launch Invokana Ketoacidosis Lawsuit Center 3Health News:Standards Considerations for Laser Safety Labels from Clarion Safety Systems Featured in In Compliance Magazine 2Health News:Standards Considerations for Laser Safety Labels from Clarion Safety Systems Featured in In Compliance Magazine 3Health News:Standards Considerations for Laser Safety Labels from Clarion Safety Systems Featured in In Compliance Magazine 4Health News:White House names Champions of Change for Precision Medicine: CareSync COO Recognized 2Health News:White House names Champions of Change for Precision Medicine: CareSync COO Recognized 3Health News:The Holiday Inn Westbury - Long Island Will Host a Fundraising Event on September 16th 2015 from 6:00 pm - 10:00 pm to Benefit Angela's House located on Long Island 2Health News:The Holiday Inn Westbury - Long Island Will Host a Fundraising Event on September 16th 2015 from 6:00 pm - 10:00 pm to Benefit Angela's House located on Long Island 3Health News:World Infectious Disease Testing Market Examined by VPGMarketResearch.com in In-Demand Report Available at MarketPublishers.com 2Health News:World Infectious Disease Testing Market Examined by VPGMarketResearch.com in In-Demand Report Available at MarketPublishers.com 3
... Reporter , TUESDAY, July 27 (HealthDay News) -- Infants born ... breathing problems compared with full-term babies, a new study finds. ... and 37th weeks of pregnancy -- account for about 9 ... researchers said. And too often, they are the result of ...
... attention-deficit/hyperactivity disorder (ADHD) the most common childhood psychiatric ... to finish high school on time than students with ... a large national study by researchers at the UC ... that nearly one third of students with ADHD, twice ...
... News) -- Weight-loss surgery, also known as bariatric surgery, ... of serious complications, a new study suggests. The ... that do the highest number of bariatric surgeries, according to ... Journal of the American Medical Association . Rates ...
... H. Zewail, Ph.D., 1999 Chemistry Nobel Laureate and Linus ... the California Institute of Technology, has been named winner ... Society (ACS). The award recognizes Zewail,s revolutionary methods ... processes in chemistry, biology and materials science. His work ...
... Reporter , MONDAY, July 26 (HealthDay News) -- Extending the ... tPA from 3 hours to up to 4.5 hours after ... in treatment and appears to be a safe option for ... slight increased risk of death and bleeding over a three-month ...
... July 26, 2010 A review of scientific studies that ... no clear answer on which treatment is better, a UT Southwestern ... the Archives of Internal Medicine . "The most ... be a mix of good and bad news," said Dr. Ethan ...
Cached Medicine News:Health News:Delivering Babies Even a Few Weeks Early Ups Respiratory Risks 2Health News:Delivering Babies Even a Few Weeks Early Ups Respiratory Risks 3Health News:ADHD, conduct disorder and smoking most strongly related to dropping out of high school 2Health News:ADHD, conduct disorder and smoking most strongly related to dropping out of high school 3Health News:ADHD, conduct disorder and smoking most strongly related to dropping out of high school 4Health News:Complications From Weight-Loss Surgery 'Relatively Low' 2Health News:American Chemical Society's highest honor goes to pioneer in 'ultraslow-motion' imaging 2Health News:American Chemical Society's highest honor goes to pioneer in 'ultraslow-motion' imaging 3Health News:Longer Time Frame for Clot-Busting Drug May Help Beat Stroke 2Health News:Longer Time Frame for Clot-Busting Drug May Help Beat Stroke 3Health News:Surgery or stenting for carotid artery disease? Question remains 2Health News:Surgery or stenting for carotid artery disease? Question remains 3
... white LED (Light Emitting Diode) light source, coupled ... the freedom of using a slit lamp anywhere ... about 1.5 lbs. (0.68 kg) with its battery ... Its ergonomic, portable design and convenient carrying ...
Powerful LED Illumination , The ultrabright and compact 3S LED HeadLight from HEINE for Powerful, coaxial illumination...
... Abnormal Control Serum is intended for monitoring the ... assays. It is for in vitro diagnostic use ... format, the control offers up to ten days ... control is to be used in accordance with ...
e-MDs Bill practice management system is used in the medical billing cycle....
Medicine Products: